<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Clin Exp Immunol 2000; 119:299&#194;&#177;304 <br />  <br />  <br />  <br />  <br />    Virulent avirulent (dhfr-ts ) Leishmania major elicit predominantly type-1 <br />                       cytokine response human cells vitro <br />  <br />    C. BRODSKYN*&#194;&#178;, S. M. BEVERLEY&#194;&#179; &amp; R. G. TITUS&#194;&#178; *Laborato&#195;&#8218;rio Imunologia, Departamento Biointerac&#195;&#8249;a&#195;&#8218;o, <br />           Instituto Cie&#195;&#402;ncias da Sau&#195;&#8218;de, Universidade Federal da Bahia, Bahia, Brazil, &#194;&#178;Department Pathology, <br />           College Veterinary Medicine Biomedical Sciences, Colorado State University, Fort Collins, CO and <br />                      &#194;&#179;Department Molecular Microbiology, Washington University, St Louis, MO, USA <br />  <br />  <br />                                                  (Accepted publication 15 October 1999) <br />  <br />  <br />  <br />                                                                  SUMMARY <br />                  In study compared immune response normal human cells cultured vitro two <br />                  virulent strains Leishmania major (CC1 LV39), avirulent vaccine strain (dhfr-ts ) made <br />                  targeted deletion essential gene DHFR-TS. We utilized vitro naive T <br />                  cells normal human donors primed autologous Leishmania-infected macrophages. All <br />                  parasites infected macrophages transformed amastigotes cells. However, <br />                  LV39 CC1 replicated macrophages, dhfr-ts did not. When peripheral blood <br />                  lymphocytes (PBL) stimulated autologous macrophages infected three <br />                  parasites, lymphocytes produced type-1-biased cytokine response. Finally, addition IL-12 <br />                  &#194;&#174;rst stimulation period increased production interferon-gamma decreased IL-5 <br />                  secretion. On hand, anti-IL-12 resulted opposite effect. <br />  <br />                  Keywords      Leishmania major macrophages          Th1    Th2 IL-12 <br />  <br />  <br />  <br />  <br />                        INTRODUCTION                                        interactions occur parasite host. An <br />                                                                            alternative method studying interactions use an <br /> Protozoan parasites genus Leishmania reside macro- <br />                                                                            vitro mimics vivo infection. Shankar &amp; Titus [3] <br /> phages, causing spectrum diseases humans ranging <span id='am-1' about='protege:FROM' typeof='owl:Thing'>from</span> <br />                                                                            developed vitro using cells lymphoid tissues of <br /> mild cutaneous lethal visceral leishmaniasis. Cell-mediated <br />                                                                            naive mice L. major promastigotes showed system <br /> immune responses critical resistance recovery from <br />                                                                            mimicked vivo responses murine leishmaniasis. Therefore, in <br /> leishmaniasis [1]. <br />                                                                            report developed vitro cell priming (IV) <br />     Cytokines central elements development an <br />                                                                            using peripheral blood mononuclear cells (PBMC) normal <br /> immune response, human experimental leish- <br />                                                                            donors assay naive peripheral blood lymphocytes <br /> maniasis received great deal attention. Cure is <br />                                                                            (PBL) sensitized autologous Leishmania-infected <br /> related predominance Th1 response, leads <span id='am-2' about='protege:TO' typeof='owl:Thing'>to</span> <br />                                                                            macrophages. <br /> the production interferon-gamma (IFN-g) activation of <br />                                                                                Recently, Titus et al. [4] tested safety vaccination <br /> parasite-infected macrophages [2]. In contrast, Th2 response <br />                                                                            potential conditional auxotroph L. major (dhfr-ts ) <br /> with production IL-4 IL-10 results disease <br />                                                                            produced targeted deletion essential metabolic gene, <br /> progression [2]. Efforts focused understanding early <br />                                                                            DHFR-TS (dihydrofolate reductase-thymidylate synthase). It was <br /> events in&#194;&#175;uence development Th1 Th2 cells the <br />                                                                            shown dhfr-ts engulfed murine macrophages, trans- <br /> interplay cytokines phenomenon order to <br />                                                                            formed amastigotes macrophages, survived mice for <br /> determine role Th development. <br />                                                                            2 months elicited substantial protective immune response in <br />     In patients infected Leishmania, dif&#194;&#174;cult estimate <br />                                                                            susceptible BALB/c mice, indicated resistance subse- <br /> the time initial infection. As result study early <br />                                                                            quent challenge virulent parasites [4]. In addition, Veras et al. <br />     Correspondence: Dr Richard Titus, Department Pathology, College     (5) observed mice vaccinated dhfr-ts partially <br /> of Veterinary Medicine Biomedical Sciences, Colorado State Univer-     protected subsequent challenge L. amazonensis. <br /> sity, Fort Collins, CO 80523, USA.                                         Therefore, studied capacity dhfr-ts sensitize PBL <br />     E-mail: rtitus@cvmbs.colostate.edu                                     IV system. <br /> q 2000 Blackwell Science                                                                                                                    299 <br />  300                                           C. Brodskyn, S. M. Beverley &amp; R. G. Titus <br />               MATERIALS AND METHODS                                            IV system <br />                                                                                The two-step IV assay used study depicted Fig. 1. From <br /> Parasites <br />                                                                                blood collection 1 obtained macrophages served as <br /> Three different types Leishmania used study: <br />                                                                                antigen-presenting cells (APC). Human blood obtained from <br /> dhfr-ts (line E-10), avirulent form L. major, produced by <br />                                                                                healthy individuals Student Health Center Colorado State <br /> targeted deletion essential metabolic gene DHFR-TS <br />                                                                                University. PBMC obtained heparinized venous blood <br /> (dihydrofolate reductase-thymidylate synthase [3]); CC1, an <br />                                                                                passage Ficoll&#194;&#177;Hypaque gradient [7]. The cells then <br /> attenuated clone L. major dhfr-ts derived; <br />                                                                                washed resuspended RPMI 1640 medium, supplemented <br /> and clone 5 LV 39 line Rho/SV/59/P, virulent clone L. <br />                                                                                2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml strepto- <br /> major passed mice 2 weeks maintain <br />                                                                                mycin, 10 mg/ml gentamycin 10% heat-inactivated AB human <br /> virulence. When used vitro experiments, Leishmania were <br />                                                                                serum (Pel-Freez; Clynical System, Brown Deer, WI), termed <br /> grown biphasic NNN medium [6] promastigotes were <br />                                                                                complete medium, concentration 4 &#194;&#180; 106 cells/ml. These <br /> harvested stationary phase growth. Because dhfrt-ts lack <br />                                                                                cells plated 24-well plates (Costar, Corning Inc., Corning, <br /> the DFHR-TS gene, conditional auxotroph was <br />                                                                                NY) incubated 2 h 378C, 5% CO2. Non-adherent cells <br /> cultured presence 10 mg/ml thymidine. <br />                                                                                removed plates adherent cells (APC-1, Fig. 1) <br />                                                                                cultured (378C, 5% CO2) complete medium 7 days. <br /> <span id='am-3' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-4' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-5' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-6' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-8' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-9' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-13' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-14' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-16' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-18' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-19' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-20' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-21' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-23' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-24' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-29' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-30' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-32' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-37' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-39' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-43' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-44' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-47' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-50' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-55' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-58' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-67' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-71' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-74' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-75' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-78' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span>Survival</span> Leishmania macrophages vitro                                 During 24 h culture, APC-1 infected dhfr-ts , <br /> In order test ability dhfr-ts survive human                    CC1 LV39 parasite:cell ratio 5:1 (348C, 5% CO2). <br /> macrophages vitro, cells adhered glass coverslips               Cultures washed order remove free parasites. <br /> in culture 7 days infected dhfr-ts , CC1                    Next, blood collected volunteer (day 7, <br /> LV39 ratio &#194;&#174;ve parasites macrophage. The                        Fig. 1) PBMC plated 4 &#194;&#180; 106 cells/ml 24-well plates <br /> coverslips removed intervals (24, 48                    order obtain autologous lymphocytes (non-adherent PBMC) <br /> 72 h), stained Diff-Quick (Scienti&#194;&#174;c Products, McGaw, IL)                 APC restimulation (adherent cells, APC-2, Fig. 1). After <br /> and examined light microscopy presence intracellular             2 h incubation (378C, 5% CO2), non-adherent PBMC were <br /> parasites.                                                                     harvested resuspended complete medium concentration <br />                                                                                4 &#194;&#180; 106 cells/ml. These cells added Leishmania-infected <br /> Cytokines monoclonal antibodies                                            APC-1 7 days 378C, 5% CO2. After incubation, the <br /> Recombinant human IL-12 (supplied Bioanalytical                         blast cells 85% CD4&#194;&#8225; T cells harvested and <br /> Sciences Department Genetics Institute, Inc., Cambridge,                    restimulated using autologous Leishmania-infected macrophages <br /> MA) used concentration 2&#194;&#180;5 mg/ml. Anti-human                       (infected APC-2, Fig. 1) 48 h 378C, 5% CO2. The super- <br /> IL-12 (clone 8.6; PharMingen, San Diego, CA) used                     natants collected kept 208C tested cytokine <br /> concentration 10 mg/ml.                                                     content ELISA. <br />  <br />  <br />  <br />                     Day 0                                     Blood collection 1 <br />  <br />  <br />  <br />                                                                                                 PBMC APC <br />                                                                                                 APC-1 <br />  <br />  <br />  <br />                                                                                                  Infection APC-1 <br />                                                           Day 6 <br />  <br />                                                               Blood collection 2 <br />                    Day 7 <br />                                                                                                Non-adherent PBMC <br />                         PBMC APC-2 <br />  <br />                                                                                               Non-adherent PBMC + <br />                    Day 13                                                                     infected APC-1 <br />  <br />                         Infection APC-2                 Day 14                                                            Day 16 <br />  <br />                                                              Stimulated non-adherent                            Supernatants <br />                                                              PBMC + infected APC-2                              ELISA <br />  <br />  <br />       Fig. 1. Experimental approach used vitro cell priming (IV) assays. From blood collection 1 APC-1 obtained, were <br />       infected 6 days different types Leishmania used study. From blood collection 2 autologous non-adherent peripheral <br />       blood mononuclear cells (PBMC) obtained incubated infected APC-1 7 days generate T cell blasts APC-2 <br />       used restimulation. Twenty-four hours harvesting blast cells (i.e. day 13), APC-2 infected different <br />       types Leishmania. On day 14 experiment, blast cells collected incubated infected APC-2 48 h. The supernatants <br />       obtained cultures analysed levels IFN-g IL-5. <br />                                                                   q 2000 Blackwell Science Ltd, Clinical Experimental Immunology, 119:299&#194;&#177;304 <br />                                                     Studies leishmaniasis using human vitro                                             301 <br /> Cytokine assays                                                                 replicate human macrophages vitro. We infected <br /> Levels IFN-g IL-5 present supernatants harvested 48 h                 human macrophages, obtained normal human donors, with <br /> after restimulation determined using commercial ELISA                  dhfr-ts , CC1 LV39 ratio &#194;&#174;ve parasites one <br /> kits (R&amp;D Systems, Minneapolis, MN).                                            macrophage. All types parasites phagocytized macro- <br />     IL-12 levels quanti&#194;&#174;ed 24, 48 96 h supernatants             phages &#194;&#174;rst 24 h (Fig. 2). Beyond 24 h, virulent Leishmania <br /> harvested infected uninfected macrophage cultures using                replicated amastigotes macrophages (Fig. 2). In contrast, <br /> immunoassay kits (R&amp;D Systems) speci&#194;&#174;c IL-12 p40 p70                    dhfr-ts did replicate. To con&#194;&#174;rm inability dhfr-ts <br /> subunits. In experiments supernatants obtained               survive macrophage lack DHFR-TS, we <br /> &#194;&#174;rst period stimulation (7 days culture presence                added thymidine (10 mg/ml) medium; restored both <br /> infected macrophages PBL) harvested                     survival replication (Fig. 2). <br /> of IFN-g, IL-5 IL-12 present supernatants was <br /> determined ELISA.                                                            Cytokine production <br />                                                                                 Using IV assay depicted Fig. 1, production IFN-g <br /> Statistical analysis                                                            IL-5 quanti&#194;&#174;ed, cytokines considered <br /> Comparisons production cytokines, using different types               representative Th1 Th2 responses, respectively [1]. In initial <br /> of Leishmania, determined using ANOVA test. Comparisons <br /> in group (to test effect cytokine anti-cytokine <br /> treatment) use Student&apos;s t-test. All tests performed <br /> using Sigma-Stat software (Microsoft System). Differences were <br /> considered signi&#194;&#174;cant P # 0&#194;&#180;05. <br />  <br />                                              RESULTS <br /> Inability dhfr-ts replicate macrophages vitro <br /> It shown dhfr-ts able replicate murine <br /> macrophages [3]. Therefore, tested parasites <br />  <br />                                       dhfr-ts&#226;&#8364;&#8220; <br />                                       dhfr-ts&#226;&#8364;&#8220; + Thymidine (10 &#194;&#181;g/ml) <br />                                       CC1 <br />                                       LV39 <br />  <br />                                1600 <br />  <br />  <br />                                1400 <br />  Amastigotes/100 macrophages <br />  <br />  <br />  <br />  <br />                                1200 <br />  <br />  <br />                                1000 <br />  <br />  <br />                                800 <br />  <br />  <br />                                600 <br />  <br />  <br />                                400 <br />  <br />  <br />                                200                                              Fig. 3. Levels IFN-g IL-5 present supernatants collected the <br />                                                                                 vitro cell priming (IV) assays. Non-adherent peripheral blood <br />                                                                                 mononuclear cells (PBMC) normal donors co-cultured with <br />                                  0 <br />                                        24            48             72          autologous infected uninfected macrophages 7 days, this <br />                                                                                 period restimulated 48 h, employing autologous <br />                                                                                 infected macrophages. Supernatants collected cytokine levels <br /> Fig. 2. Inability dhfr-ts replicate human macrophages vitro.        determined ELISAs. (a) Production IFN-g (pg/ml). (b) Production of <br /> Human macrophages obtained peripheral blood mononuclear cells              IL-5 (pg/ml). Each triangle represents individual donor. Concentrations <br /> (PBMC) infected stationary phase Leishmania 5:1 ratio            IFN-g IL-5 cultures uninfected macrophages been <br /> (Leishmania:macrophage). At indicated times, cells &#194;&#174;xed, stained       subtracted. The levels IFN-g obtained cultures uninfected <br /> with Diff-Quick examined light microscopy number              macrophages ranged 0&#194;&#180;0 270&#194;&#180;0 pg/ml levels IL-5 <br /> intracellular parasites. One macrophages/donor counted        cultures 0&#194;&#180;0 5&#194;&#180;5 pg/ml. There no <br /> time number intracellular amastigotes. Results shown      signi&#194;&#174;cant differences (P &gt; 0&#194;&#180;05) different groups infected with <br /> mean 6 s.e.m. samples group.                                  dhfr-ts , CC1 LV39 concerning production IFN-g IL-5. <br />  <br /> q 2000 Blackwell Science Ltd, Clinical Experimental Immunology, 119:299&#194;&#177;304 <br />  302                                           C. Brodskyn, S. M. Beverley &amp; R. G. Titus <br /> experiments attempted measure IL-4 production the <br /> cultures, IL-4 consistently detected, presumably <br /> because consumption cytokine proliferating cells. <br /> Figure 3 shows concentration IFN-g IL-5 obtained using <br /> Leishmania-infected adherent cells (APC) autologous non- <br /> adherent cells. All types parasites able induce the <br /> production IFN-g signi&#194;&#174;cant differences observed <br /> between responses generated using dhfr-ts , CC1 L. major <br /> (P &gt; 0&#194;&#180;05). No signi&#194;&#174;cant differences observed con- <br /> cerning production IL-5, PBMC donors                Fig. 5. Effect IL-12 IFN-g (a) IL-5 (b) production obtained after <br /> did produce cytokine IV assay. Based            stimulation non-adherent peripheral blood mononuclear cells (PBMC) <br /> results conclude donors (6/10) used              autologous Leishmania-infected macrophages normal human <br /> study secreted high amounts IFN-g, IL-5 production                donors. Non-adherent PBMC different donors exposed to <br /> practically non-detectable (&lt; 10 pg/ml). Thus, cells              autologous dhfr-ts -infected macrophages 7 days presence or <br /> donors produced predominantly type-1 cytokines. However,                     absence IL-12, period blast cells restimulated with <br />                                                                              autologous dhfr-ts -infected macrophages 48 h. The supernatants were <br /> three donors produced IL-5 signi&#194;&#174;cant amounts addition to <br />                                                                              collected IFN-g IL-5 levels determined ELISA. The <br /> IFN-g, characteristic Th0 response. One donors          differences groups treatment (absence presence of <br /> was considered non-secretor, IFN-g               IL-12) statistically signi&#194;&#174;cant (P &lt; 0&#194;&#180;05) concerning secretion of <br /> IL-5 produced low. It noted pro&#194;&#174;le            IFN-g IL-5. <br /> cytokines observed altered supernatants were <br /> harvested 7 days culture using Leishmania-infected APC-1 <br /> or 48 h second stimulation using infected APC-2 (data          collected supernatants cultures 24, 48 96 h later. We <br /> shown).                                                                      detect IL-12 cultures (data shown). <br />                                                                              However, autologous PBL cultured Leishmania- <br /> Importance IL-12 generation Th1 responses                       infected macrophages 7 days, IL-12 produced (Fig. 4). No <br /> IL-12 received great deal attention leishmaniasis,         signi&#194;&#174;cant differences IL-12 secretion observed the <br /> responsible development Th1 response. Therefore,             different groups infected dhfr-ts , CC1 LV39 (P &gt; 0&#194;&#180;05). <br /> determined IL-12 produced IV system. We                       In order determine importance IL-12 develop- <br /> infected macrophages dhfr-ts , CC1 LV 39                  ment Th1 response IV system, cultures initiated in <br />                                                                              presence absence recombinant human IL-12 anti- <br />                                                                              human IL-12. The cytokine antibody added cultures <br />       250                                                                    &#194;&#174;rst stimulation PBL, using infected macrophages as <br />                                                                              APC. After primary stimulation, blasts harvested and <br />                                                                              restimulated autologous infected macrophages APC the <br />       200                                                                    absence IL-12 anti-IL-12. As shown Fig. 5, IL-12 <br />                                                                              signi&#194;&#174;cantly increased production IFN-g (P &lt; 0&#194;&#180;05) from <br />                                                                              cells donors tested (Fig. 5a). On hand, cytokine <br />       150 <br />                                                                              led signi&#194;&#174;cant decrease (P &lt; 0&#194;&#180;05) secretion IL-5 to <br />                                                                              levels non-detectable (Fig. 5b). <br />       100 <br />  <br />  <br />        50 <br />  <br />  <br />         0 <br />  <br />  <br />  <br />                     dhfr-ts&#226;&#8364;&#8220;        CC1           LV39 <br />  <br />                                  Treatment <br /> Fig. 4. IL-12 cultures Leishmania-infected macrophages non- <br /> adherent peripheral blood mononuclear cells (PBMC). Macrophages         Fig. 6. Effect anti-IL-12 IFN-g (a) IL-5 (b) production obtained <br /> 10 different donors infected dhfr-ts , CC1 LV39     stimulation non-adherent peripheral blood mononuclear cells <br /> ratio &#194;&#174;ve parasites macrophage. After washing remove free       (PBMC) autologous Leishmania-infected macrophages normal <br /> parasites, autologous non-adherent PBMC added cultures       human donors. Non-adherent PBMC &#194;&#174;ve different donors were <br /> incubated 7 days 378C, 5% CO2. At point supernatants    exposed autologous dhfr-ts -infected macrophages 7 days the <br /> harvested IL-12 levels determined ELISA speci&#194;&#174;c       presence absence anti-IL-12, and, period blast cells were <br /> p40 p70 subunits IL-12. Concentrations IL-12 produced           restimulated autologous dhfr-ts -infected macrophages 48 h. The <br /> cultures uninfected macrophages subtracted. The levels     supernatants collected IFN-g IL-5 levels deter- <br /> IL-12 obtained cultures uninfected macrophages        mined ELISA. There signi&#194;&#174;cant differences (P &lt; 0&#194;&#180;05) the <br /> 9&#194;&#180;0 70&#194;&#180;0 pg/ml. There signi&#194;&#174;cant differences (P &gt; 0&#194;&#180;05)          groups treatment (absence presence anti-IL-12) concerning the <br /> between different groups infected dhfr-ts , CC1or LV39.             production IFN-g IL-5. <br />                                                                   q 2000 Blackwell Science Ltd, Clinical Experimental Immunology, 119:299&#194;&#177;304 <br />                                       Studies leishmaniasis using human vitro                                                  303 <br />     The role endogenous IL-12 examined using anti-            Leishmania induce contrasting signals leading production <br /> IL-12 &#194;&#174;rst stimulation PBL. As shown Fig. 6,         tumour necrosis factor-alpha (TNF-a), leads macro- <br /> presence anti-IL-12 primary stimulation led            phage activation, production transforming growth <br /> signi&#194;&#174;cant decrease production IFN-g (Fig. 6a) cells       factor-beta (TGF-b) IL-10, linked macrophage <br /> of &#194;&#174;ve donors tested (P &lt; 0&#194;&#180;05). In addition, anti-IL-12              deactivation inhibition IFN-g [13,14]. The in&#194;&#175;uence of <br /> enhanced production IL-5 (Fig. 6b) cells              IFN-g produced natural killer (NK) cells, depend <br /> donors (P &lt; 0&#194;&#180;05). It interesting presence antibody   IL-12, involved initial Th1 development [15]. Initial <br /> during primary stimulation PBL donors, normally           survival Leishmania inside macrophage probably depends <br /> did produce IL-5, induced secretion cytokine,             similar cytokines predominate micro- <br /> showing importance IL-12 generation different            environment infection. Our IV model allows study early <br /> Th responses.                                                             events phagocytosis Leishmania macrophages as <br />                                                                           modulation immune responses addition cytokines <br />                                                                           anti-cytokines. <br />                           DISCUSSION <br />                                                                               IL-12 received great deal attention leishmaniasis. <br /> The results vitro priming shown              The cytokine produced following infection mice L. major <br /> correlate vivo responses murine leishmaniasis [3]. Here        [16,17] important control Th2 expansion promote <br /> we succeeded generating autologous              predominance Th1-type response [18&#194;&#177;20]. In addition, <br /> infected macrophages serve APC priming PBL normal             treatment susceptible mice IL-12 renders resistant <br /> human donors. This IV approach allowed examine inter-               [19,21,22]. Moreover, IL-12 used effective adjuvant <br /> actions occur infected APC PBL. Such inter-              killed vaccine L. major [23]. In contrast vivo <br /> actions in&#194;&#175;uence overall response infection               results, L. major inhibits IL-12 production infected murine <br /> Leishmania outcome disease. These studies            macrophages vitro [17,24]. Similar studies mice, we <br /> are possible using cells patients leishmaniasis       detect secretion IL-12 L. major-infected macro- <br /> it impossible determine patient infected       phages, suggesting parasites induce production <br /> the parasite.                                                             cytokine human macrophages. Interestingly, however, <br />      We analysed ability different Leishmania parasites      addition autologous PBL infected macrophage cultures <br /> to prime T cells IV system: dhfr-ts , CC1 L. major             resulted detectable production IL-12 (Fig. 4). This suggests <br /> (strain LV39). Although dhfr-ts engulfed macrophages,           signals delivered PBL, CD40&#194;&#177;CD40L [25], <br /> did replicate inside cells (Fig. 2). Interestingly, despite   important up-regulation IL-12 production by <br /> fact dhfr-ts did replicate macrophages, elicited       human macrophages infected L. major. It men- <br /> type immune response (potentially protective IFN-g little         tioned contrast results study L. major, <br /> IL-5) did CC1 LV39 (Fig. 3). Thus, dhfr-ts                Russo et al. [8] observed IL-12 secretion L. amazonensis- <br /> avirulent induces protective immune response,          infected macrophages 96 h infection. This apparent <br /> an acceptable vaccine candidate human use.                            difference explained use different strains of <br />      Evaluating cytokine production (IFN-g IL-5) response          Leishmania; progression infection L. amazonensis in <br /> to stimulation parasite-infected macrophages, observed            mice shown distinct L. major [26]. <br /> that donors elicited Th1 Th0 <span id='am-81' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-82' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-83' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-84' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-85' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-86' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-87' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-90' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-92' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-93' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-94' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-95' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-96' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-97' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-98' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-99' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-100' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-101' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-104' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-105' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-107' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-108' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-111' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-112' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-113' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-115' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-117' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-122' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-123' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-125' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-127' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-130' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-131' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-133' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-135' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-136' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-139' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-141' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-142' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-143' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-144' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-146' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-151' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-154' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-156' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span>phenotype</span>. Of 10 donors                Studies human leishmaniasis con&#194;&#174;rm relevant roles of <br /> tested, showed Th1 pro&#194;&#174;le, Th0 considered         IFN-g IL-12 major cytokines involved host protection <br /> a non-secretor. Similar results obtained Russo et al. [8],        [1]. Therefore, studying effects IL-12 anti-IL-12 our <br /> who developed vitro study early responses            IV important understand development of <br /> unexposed individuals L. amazonensis infection. The authors            Leishmania-speci&#194;&#174;c Th1 responses. As depicted Fig. 5, IL-12 <br /> obtained different cell lines different donors veri&#194;&#174;ed      completely abrogated Th2 responses, increasing signi&#194;&#174;cantly the <br /> most classi&#194;&#174;ed Th1 Th0 responders.                 secretion IFN-g abolishing production IL-5 cells <br /> Therefore, independent Leishmania used, human cells                donors stimulated Leishmania-infected macro- <br /> produce similar cytokine pro&#194;&#174;le.                                        phages. On hand, presence anti-IL-12 the <br />      Subauste et al. [9], studying responses unexposed           IV promoted Th2 response, signi&#194;&#174;cant decrease IFN-g <br /> individuals Toxoplasma gondii infection in vitro model,          production increase IL-5 (Fig. 6), showing important <br /> observed intense proliferation CD4&#194;&#8225; ab T cells,           role IL-12 differentiation human Th1 Th2 <br /> cells secreted signi&#194;&#174;cant IFN-g. Therefore,         responses. Therefore, vaccine potential dhfr-ts leish- <br /> rapid T cell response play important role early             maniasis enhanced transfecting parasite with <br /> response intracellular parasites. Indeed, recent work Launois       cytokine genes (e.g. IL-12) favour development Th1 <br /> et al. [10] showed large amounts cytokines (IL-4          responses. <br /> their work) secreted mouse ab T cells &#194;&#174;rst 16 h <br /> after infection L. major. Finally, results obtained                          ACKNOWLEDGMENTS <br /> experiments concerning production IFN-g IL-5 are <br />                                                                           We thank Genetic Institute providing human recombinant IL-12, <br /> similar observed leishmaniasis patients; the <br />                                                                           Monica Estay technical assistance Dr Greg DeKrey Dr <br /> patients self-healing cutaneous leishmaniasis strong            Lamine Mbow critical review manuscript. This study received <br /> Th1 responses [2,11] or, early infection, Th0 <span id='am-237' about='xsp:pattern' typeof='owl:Thing'>pattern</span> [12].      &#194;&#174;nancial support NIH AI-29955 (R.G.T.), NIH AI 29646 WHO <br />      The Th1&#194;&#177;Th2 dichotomy probably in&#194;&#175;uenced cyto-             Special Programme Tropical Disease Research (S.M.B.). C.B. received a <br /> kines produced early stages Leishmania survival            fellowship CAPES/Fulbright 1997 CAPES-Brasilia/ <br /> inside macrophage. Upon entry human macrophages,                 Brazil 1998. <br /> q 2000 Blackwell Science Ltd, Clinical Experimental Immunology, 119:299&#194;&#177;304 <br />  304                                           C. Brodskyn, S. M. Beverley &amp; R. G. Titus <br />                                                                              14 Barral-Netto M, Badaro R, Barral A et al. Tumor necrosis factor <br />                           REFERENCES <br />                                                                                 (cachectin) human visceral leishmaniasis. J Infec Dis 1991; <br />  1 Barral-Netto M, Machado P, Bittencourt AL, Barral A. Recent                  163:853&#194;&#177;7. <br />    advances pathophysiology treatment human cutaneous              15 Scharston-Kersten T, Scott P. The role innate immune response in <br />    leishmaniasis. Curr Opin Dermatol 1997; 4:51&#194;&#177;8.                              Th1 cell development following Leishmania major infection. J Leuk <br />  2 Carvalho EM, Correia Filho D, Bacellar O, Almeida RP, Rocha E.               Biol 1995; 57:515&#194;&#177;22. <br />    Characterization immune response subjects self-healing     16 Sypek JP, Chung CL, Mayor SE et al. Resolution cutaneous <br />    cutaneous leishmaniasis. Am J Trop Med Hyg 1995; 53:273&#194;&#177;7.                   leishmaniasis: interleukin 12 initiates protective T helper type 1 <br />  3 Titus RG, Gueiros-Filho FJ, Freitas LA, Beverley SM. Development          immune response. J Exp Med 1993; 177:1797&#194;&#177;802. <br />    safe live Leishmania vaccine line gene replacement. Proc Natl        17 Reiner SL, Zheng S, Wang ZE, Stowring L, Locksley RM. Leishmania <br />    Acad Sci USA 92 1995; 92:10267&#194;&#177;71.                                           promastigotes evade interleukin 12 (IL-12) stimulate broad range <br />  4 Shankar AH, Titus RG. Leishmania-major-speci&#194;&#174;c, CD4&#194;&#8225;, major                  cytokines CD4&#194;&#8225; T cells initiation infection. J Exp <br />    histocompatibility complex class II-restricted T cells derived          Med 1994; 179:447&#194;&#177;56. <br />    lymphoid tissues naive mice. J Exp Med 1993; 78:101&#194;&#177;11.                18 Scharston-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P. <br />  5 Veras P, Brodskyn CI, Balestieri FM, Freitas LAR, Ramos APS,                 IL-12 required natural killer activation subsequent <br />    Queiroz ARP, Beverly SM, Barral-Netto MA. dhfr-ts Leishmania                 development experimental leishmaniasis. J Immunol 1995; <br />    major <span id='am-159' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-160' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-161' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-162' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-163' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-164' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-165' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-166' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-167' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-169' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-170' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-171' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-172' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-173' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-174' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-175' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-176' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-177' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-179' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-180' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-181' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-182' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-184' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-185' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-186' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-187' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-188' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-190' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-191' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-192' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-193' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-194' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-195' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-196' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-197' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-198' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-199' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-202' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-203' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-205' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-206' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-207' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-208' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-210' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-211' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-212' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-213' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-214' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-217' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-218' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-219' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-220' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-221' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-222' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-223' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-224' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-225' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-226' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-227' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-228' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-229' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-230' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-231' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-232' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-235' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span>knockout</span> mutant cross protects Leishmania amazonensis.         154:5320&#194;&#177;30. <br />    Memorias Instituto Osvaldo Cruz 1999; 94:491&#194;&#177;6.                        19 Murray HW, Hariprashad J, Coffman RL. Behavior visceral <br />  6 Titus RG, Muller I, Kimsey P, Cerny A, Behin R, Zinkernagel RM,              Leishmania donovani experimentally induced T helper 2 (Th2)- <br />    Louis JA. Exacerbation experimental murine cutaneous leish-               associated response model. J Exp Med 1997; 185:867&#194;&#177;74. <br />    maniasis CD4&#194;&#8225; Leishmania major-speci&#194;&#174;c <br /> </body></html>